AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

169.500

-1.710-1.00%

Volume:1.09M

Turnover:184.05M

Market Cap:81.18B

PE:-22.68

High:170.190

Open:169.660

Low:166.680

Close:171.210

52wk High:216.748

52wk Low:88.836

Shares:478.91M

Float Shares:478.91M

Volume Ratio:1.06

T/O Rate:0.23%

Dividend:4.08

Dividend Rate:2.41%

EPS(TTM):-7.473

EPS(LYR):-7.473

ROE:-15.83%

ROA:7.26%

PB:3.93

PE(LYR):-22.68

Loading ...

Overview Company News Filings

Asia Morning Call-Global Markets

ASX Midday Sector Update: Healthcare Stocks Lead Broad-Based Rally

MT Newswires Live

Australia's CSL Rises on Launching Trials for Patented Manufacturing Process

CSL to Conduct Trial Work to Confirm Efficacy, Safety of Immunoglobulin Produced Via Proprietary Process; Shares Jump 6%

MT Newswires Live

Stock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement

Horizon 2 Technology Enables Greater Immunoglobulin Production

THOMSON REUTERS

To Launch Clinical Trials for Horizon 2 Immunoglobulin Process

THOMSON REUTERS

CSL Ltd - to Launch Clinical Trials to Evaluate Enhanced Plasma Manufacturing

THOMSON REUTERS

To Seek FDA and Ema Approval for Horizon 2

THOMSON REUTERS

CSL Ltd - Will Undertake Clinical Trial Work to Confirm Efficacy and Safety of Immunoglobulin Manufactured Using Its Next Generation Horizon 2 Process

THOMSON REUTERS

To Commence Horizon 2 Clinical Activities in Mid-2027

THOMSON REUTERS

ASX Dividend Stocks For Steady Income in Uncertain Markets

Simply Wall St.

CSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry

MT Newswires Live

Andembry Showed Favorable Safety; Majority Remained Attack-Free During 12-Month Treatment Period

THOMSON REUTERS

CSL Reports Positive Top-Line Phase 3B Results Supporting Planned Expanded Pediatric Filing for Andembry® (Garadacimab-Gxii) in Children with Hereditary Angioedema (Hae)

THOMSON REUTERS

To Submit Filings for Expanded Pediatric Indication for Andembry in First Half of Fiscal Year

THOMSON REUTERS

CSL Stock And 2 More Australian Income Shares For Steady Dividends

Simply Wall St.

CSL Stock And 2 Australian Dividend Shares For Reliable Income

Simply Wall St.

3 Australian Dividend Stocks Offering Yield When Reliable Income Is Hard To Find

Simply Wall St.

CSL Bull Positive on Outlook for Immunoglobulin

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/CSL.AU/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":169.5,"timestamp":1789020720000,"preClose":171.21,"halted":0,"volume":1090729,"delay":0,"changeRate":-0.009987734361310717,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.473319550762698,"marketStatus":"Not Yet Opened","change":-1.71,"latestTime":"09-10 16:12:00 AEST","open":169.66,"high":170.19,"low":166.68,"amount":184052300,"amplitude":0.020501,"askPrice":169.58,"askSize":200,"bidPrice":168.5,"bidSize":980,"shortable":3,"etf":0,"ttmEps":-7.473319550762698,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":171.21,"dividendRate":0.02404,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":1.0589420996301422,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":171.21,"auctionPrice":169.5,"auctionVolume":397713,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020604080}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.473111,"volumeRatio":1.0589420996301422,"shares":478911979,"dividePrice":4.078782,"high":170.19,"amplitude":0.020501,"preClose":171.21,"low":166.68,"week52Low":88.836,"pbRate":"3.93","psRate":"3.68","week52High":216.748,"institutionHeld":0,"latestPrice":169.5,"committee":0.661017,"eps":-7.473110769660567,"divideRate":0.024064,"volume":1090729,"delay":0,"ttmEps":-7.473110769660567,"open":169.66,"prevYearClose":168.21,"prevWeekClose":172.243,"prevMonthClose":169.351,"prevQuarterClose":113.256,"fiveDayClose":173.23,"twentyDayClose":135.741,"sixtyDayClose":106.682,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.01866467227077263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655818139","title":"Asia Morning Call-Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2655818139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655818139?lang=en_us&edition=fundamental","pubTime":"2026-07-30 02:32","pubTimestamp":1785349969,"startTime":"0","endTime":"0","summary":"Asia Morning Call-Global MarketsJuly 30 (Reuters)-Stock MarketsNet ChngStock MarketsNet ChngS&P/ASX 200**9,038.6090.80NZX 50**13,976.67114.74DJIA51,932.67-814.65NIKKEI**61,434.19-930.73Nasdaq24,779.13","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4N43V1ZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0264606111.USD","LU0345780950.USD","LU0345781412.USD","LU0654597011.USD","LU1267930730.SGD","LU2210149790.SGD","LU0572940350.SGD","SG9999001143.SGD","BK7507","BK5111","LU2265009873.SGD","LU1804176565.USD","MSCI","LU1064927863.SGD","BK7501","LU0955669360.SGD","CSL.AU","LU0456854461.SGD","LU1309081286.SGD","BK4112","FDIQ","LU0612318971.USD","IE00B3M56506.USD","LU0161305163.EUR","BK4585","LU1130305938.SGD","IE0034235071.USD","LU0171293334.USD","LU0289739343.SGD","LU1023059493.AUD","LU0971552673.USD","LU0831103253.SGD","RIO.UK","LU0011963245.USD","LU0289960550.SGD","LU2095319765.USD","LU0898667661.SGD","LU0345777147.USD","SG9999002521.SGD","BK7095","LU0266512473.USD","LU0320765059.SGD","LU0390134368.USD","LU0266512127.USD","RIO.AU","LU1481600234.SGD","LU0345777659.USD","LU0708995401.HKD","LU0955648018.USD","LU0572939691.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655830439","title":"ASX Midday Sector Update: Healthcare Stocks Lead Broad-Based Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2655830439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655830439?lang=en_us&edition=fundamental","pubTime":"2026-07-29 10:58","pubTimestamp":1785293913,"startTime":"0","endTime":"0","summary":"Healthcare stocks jumped nearly 4%, leading a broad-based rally at midday Wednesday.CSL  gained almost 7% in recent trade following news that it will conduct clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its Horizon 2 process.Meanwhile, the financial sector edged up nearly 1%.Commonwealth Bank  shares inched up in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7511","LU0029874061.USD","BK4588","CBA.AU","XLV","BK4581","BK7501","CSL.AU","BK7135","XBI","BK4585","BK4137","BK7508","DBB","HCSG","LU0128526141.USD","BK7067","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655783450","title":"Australia's CSL Rises on Launching Trials for Patented Manufacturing Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2655783450","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655783450?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:54","pubTimestamp":1785286492,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL rises on launching trials for patented manufacturing process** Shares of biotechnology major CSLCSL.AXrise 5.6% to A$126.59, their highest since July 9** Stock on track for best d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4N43V02K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CSL.AU","BK7511","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655083457","title":"CSL to Conduct Trial Work to Confirm Efficacy, Safety of Immunoglobulin Produced Via Proprietary Process; Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655083457","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655083457?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:53","pubTimestamp":1785286428,"startTime":"0","endTime":"0","summary":"CSL  will conduct clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its Horizon 2 process, according to a Wednesday Australian bourse filing.The company said it expects clinical activities to start in mid-2027.The process enables greater production of immunoglobulin from the same base amount of plasma, per the filing.The company said it will obtain clinical evidence to support and finalize regulatory approval processes for Horizon 2 after its engagements with the US Food and Drug Administration and European Medicines Agency.CSL's shares rose nearly 6% in recent trading on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CSL.AU","LU0728928796.USD","BK7508","CSL","BK7511","LU1169589451.USD","BK7501","SGXZ23171101.USD","LU1169590202.USD","BK4086","SG9999004303.SGD","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137947072","title":"Stock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1137947072","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137947072?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:14","pubTimestamp":1785284061,"startTime":"0","endTime":"0","summary":"Shares of CSL Limited surged 5.00% during intraday trading on Wednesday, following the company's announcement that it will launch clinical trials for its next-generation Horizon 2 immunoglobulin...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655883986","title":"Horizon 2 Technology Enables Greater Immunoglobulin Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2655883986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655883986?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7508","BK7511","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655878839","title":"To Launch Clinical Trials for Horizon 2 Immunoglobulin Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2655878839","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655878839?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CSL.AU","BK7508","BK7511","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655839865","title":"CSL Ltd - to Launch Clinical Trials to Evaluate Enhanced Plasma Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2655839865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655839865?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","BK7501","BK7511","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655839820","title":"To Seek FDA and Ema Approval for Horizon 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2655839820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655839820?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7067","BK7501","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655398668","title":"CSL Ltd - Will Undertake Clinical Trial Work to Confirm Efficacy and Safety of Immunoglobulin Manufactured Using Its Next Generation Horizon 2 Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2655398668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655398668?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7511","BK7501","BK7067","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655383987","title":"To Commence Horizon 2 Clinical Activities in Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2655383987","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655383987?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CSL.AU","BK7508","BK7511","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654885173","title":"ASX Dividend Stocks For Steady Income in Uncertain Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2654885173","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654885173?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:24","pubTimestamp":1785245055,"startTime":"0","endTime":"0","summary":"With inflation signals mixed, central banks cautious and bond yields reacting to every new headline, many investors are looking for steadier income from their portfolios. That is where the Dividend Powerhouses screener comes in. It focuses on companies offering more than a 5% dividend yield that is covered, growing and stable, which can help you keep cash flow coming even as markets adjust to changing energy costs, policy risks and shifting trade patterns. In this article you will see three...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/asx-dividend-stocks-for-steady-income-in-uncertain-markets","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/asx-dividend-stocks-for-steady-income-in-uncertain-markets","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7501","BK7034","CSL.AU","PICK","EVN.AU","BK7511","GLTR","BK7506","BK7104","PMDE","QBE.AU","BK4535","VIG","BK4588","BK7067","BK4585","CEF","VOTE","DECU","XME","UYM","GBUG","BEGS","GOAU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654022877","title":"CSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry","url":"https://stock-news.laohu8.com/highlight/detail?id=2654022877","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654022877?lang=en_us&edition=fundamental","pubTime":"2026-07-28 09:52","pubTimestamp":1785203526,"startTime":"0","endTime":"0","summary":"CSL's  Andembry drug showed a favorable safety and tolerability profile in a phase 3b study in children aged between two and 11 years with hereditary angioedema, a genetic disorder characterized by severe swelling, according to a late Monday statement.The company said it observed treatment response across the study population, with most of the participants remaining attack-free during the 12-month treatment period.The topline results support CSL's plan to seek an expanded pediatric indication for Andembry, and the company intends to start submitting filings to health authorities in the first half of its fiscal year.CSL shares gained 1% in recent Tuesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999004303.SGD","BK4086","LU1169589451.USD","LU0728928796.USD","CSL","BK7501","BK7508","CSL.AU","SGXZ23171101.USD","BK7511","BK7067","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654671048","title":"Andembry Showed Favorable Safety; Majority Remained Attack-Free During 12-Month Treatment Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2654671048","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654671048?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA2NHVBF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7508","BK7067","BK7501","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654304862","title":"CSL Reports Positive Top-Line Phase 3B Results Supporting Planned Expanded Pediatric Filing for Andembry® (Garadacimab-Gxii) in Children with Hereditary Angioedema (Hae)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654304862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654304862?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA2NHVBF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048640","title":"To Submit Filings for Expanded Pediatric Indication for Andembry in First Half of Fiscal Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048640?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA2NHVBF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","BK7508","CSL.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654147170","title":"CSL Stock And 2 More Australian Income Shares For Steady Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2654147170","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654147170?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:20","pubTimestamp":1785147619,"startTime":"0","endTime":"0","summary":"With inflation, interest rates and energy prices all pulling at your portfolio from different directions, dependable dividend income can feel more valuable than ever. The Dividend Powerhouses (3%+ Yield) screener focuses on companies that offer more than a 5% yield, with payouts that are covered by earnings, have a record of growth and show stability through changing economic conditions. This combination can help you keep cash flowing while markets reassess growth, central bank paths and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-more-australian-income-shares-for-steady-div","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-more-australian-income-shares-for-steady-div","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GLD","RING","DUST","PHYS","BAR","CSL.AU","PPI","AAAU","XME","IAUM","CEF","DGP","DZZ","GDXY","CSL","GDX","USG","JDST","SGDM","IAU","UGL","GLL","UYM","XJO.AU","SGOL","SHNY","GDXJ","BEGS","OUNZ","XAO.AU","FGDL","DBC","DULL","IAUI","GOLY","DACE.AU","GOAU","GLDM","BTGD","GLTR","PICK","GDXU","XKO.AU","EVN.AU","GBUG","JNUG","QBE.AU","VAS.AU","VIG","GDXD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654563540","title":"CSL Stock And 2 Australian Dividend Shares For Reliable Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2654563540","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654563540?lang=en_us&edition=fundamental","pubTime":"2026-07-25 12:40","pubTimestamp":1784954429,"startTime":"0","endTime":"0","summary":"With inflation, energy prices and central bank policies all pulling investors in different directions, reliable income has fresh appeal. Dividend Powerhouses aim to offer just that, with stocks yielding more than 5% and dividends that are covered, growing and relatively stable. Instead of chasing the latest story, this approach focuses on companies that pay you to stay invested while you watch how inflation, growth data and policy shifts play out. In this article, three stocks from the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-australian-dividend-shares-for-reliable-inco","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-australian-dividend-shares-for-reliable-inco","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IAUM","GBUG","UYM","BTGD","PPI","BEGS","BAR","XKO.AU","XME","BBOZ.AU","GOAU","EVN.AU","CSL.AU","IAU","GDXD","OZR.AU","GDXY","XAO.AU","AAAU","PICK","RING","NST.AU","CEF","JNUG","FGDL","OUNZ","SGDM","GDXU","GLL","SHNY","DUST","JDST","SGOL","DBC","PHYS","DGP","GOLY","GLTR","GEAR.AU","GLDM","DULL","IAUI","CSL","DZZ","GDX","UGL","XJO.AU","VAS.AU","GDXJ","USG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653745983","title":"3 Australian Dividend Stocks Offering Yield When Reliable Income Is Hard To Find","url":"https://stock-news.laohu8.com/highlight/detail?id=2653745983","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653745983?lang=en_us&edition=fundamental","pubTime":"2026-07-23 17:23","pubTimestamp":1784798629,"startTime":"0","endTime":"0","summary":"With central banks weighing inflation risks, bond yields climbing, and energy costs staying elevated, dependable income has become harder to find without taking on extra stress. That is where the Dividend Powerhouses (3%+ Yield) screener comes in. It focuses on companies paying more than a 5% dividend yield that is covered by earnings, growing, and relatively stable. For investors who want cash flow that does not depend solely on price moves, this kind of discipline can be useful. In this...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-australian-dividend-stocks-offering-yield-when-reliable-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-australian-dividend-stocks-offering-yield-when-reliable-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RING","DUST","PHYS","PMDE","BAR","CSL.AU","PPI","AAAU","XME","IAUM","CEF","DGP","DZZ","GDXY","USG","GDX","JDST","SGDM","VOTE","IAU","UGL","GLL","UYM","XJO.AU","SGOL","SHNY","GDXJ","BEGS","DECU","OUNZ","XAO.AU","FGDL","DBC","DULL","IAUI","GOLY","GOAU","SPHQ","GLDM","BTGD","GLTR","PICK","GDXU","XKO.AU","EVN.AU","GBUG","JNUG","QBE.AU","VIG","GDXD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653478115","title":"CSL Bull Positive on Outlook for Immunoglobulin","url":"https://stock-news.laohu8.com/highlight/detail?id=2653478115","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653478115?lang=en_us&edition=fundamental","pubTime":"2026-07-22 07:46","pubTimestamp":1784677560,"startTime":"0","endTime":"0","summary":"2346 GMT - Pharmaceutical company CSL keeps Morgan Stanley as a bull after reviewing the outlook for immunoglobulin and albumin. MS sees EPS falling 3% and 2% in FY 2026 and 2027, respectively, before rebounding to 8% growth annually over FY 2028-2030. MS stays positive on immunoglobulin's outlook. \"Over the medium to longer-term, we continue to see opportunities in primary and secondary immunodeficiency , key drivers of our industry volume growth forecast of 5.5% per annum through to 2030,\" MS says. In China, it expects regulatory changes to moderate volume growth and hurt selling prices. MS pares forecasts for immunoglobulin and albumin revenue growth. \"However, benefits from immunoglobulin yield initiatives  should support margin expansion within CSL Behring, with our forecasts implying a gross margin of 54.5% by FY32,\" MS says.  Dow Jones NewswiresJuly 21, 2026 19:46 ET Copyright  2026 Dow Jones & Company, Inc.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU1244550221.USD","LU1720051108.HKD","LU2089284900.SGD","BK4086","LU0912757837.SGD","LU1791710582.SGD","LU1989772923.USD","LU2111349929.HKD","LU2271345857.HKD","LU0053666078.USD","LU1064131342.USD","LU0528227936.USD","LU1169590202.USD","LU2028103732.USD","LU1791710400.SGD","LU2357305700.SGD","LU0320765646.SGD","BK7511","CSL","LU1732799900.SGD","LU0882574139.USD","LU1074936037.SGD","SG9999004303.SGD","LU0158827948.USD","LU1244550494.USD","LU0390134368.USD","LU2023251221.USD","LU0225283273.USD","LU1548497426.USD","LU1989772840.SGD","LU1668664300.SGD","KBWB","LU0210528500.USD","LU1732800096.USD","LU2089283258.USD","LU0728928796.USD","LU0006306889.USD","LU1988902786.USD","IAI","LU2487616109.SGD","LU1162221912.USD","LU0098860793.USD","LU0557290698.USD","CSL.AU","BK7067","BK4534","LU2264538146.SGD","BK4588","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}